Experimental Weight Loss Drugs Show Promise of Higher Efficacy and Arrival in Pill Form

Novo Nordisk and Eli Lilly have developed oral and injectable drugs that have helped patients lose up to 24% of their body weight in clinical trials.
Eli Lilly's retatrutide and oral semaglutide led to the highest weight loss seen yet in the obesity treatment space.
The new drugs work by mimicking hormones that suppress appetite and slow stomach emptying.
The drugs may soon seek FDA approval, with Novo Nordisk planning to file for approval of an oral semaglutide pill this year.
If approved, the new weight loss drugs could transform the $100 billion market, offering more effective options in pill form.